Developer docs
API playgroundTry for free, no card

Search company profiles

Prime Medicine

Full company profile

uuid00002za

Namestring
Prime Medicine
Legal namestring
Prime Medicine, Inc.
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Prime Medicine, Inc. is a clinical-stage biotechnology company founded in 2019/2020 and headquartered at 21 Erie Street in Cambridge, Massachusetts, that develops Prime Editing-based gene editing therapies for rare genetic diseases. The company's core platform, Prime Editing, was developed in Dr. David R. Liu's lab at the Broad Institute of MIT and Harvard and published in Nature in December 2019; it acts as a "DNA word processor" to search and replace genetic sequences at their native genomic location without inducing double-strand DNA breaks, theoretically addressing approximately 90% of known disease-causing mutations. The product portfolio spans three therapeutic areas: hematology/immunology/oncology (PM359, an ex vivo autologous HSC therapy for p47phox Chronic Granulomatous Disease, and ex vivo CAR-T programs partnered with Bristol Myers Squibb), liver diseases (PM577a for H1069Q-mutated Wilson Disease via LNP delivery, and PM647 for Alpha-1 Antitrypsin Deficiency), and lung disease (a cystic fibrosis program supported by Cystic Fibrosis Foundation funding targeting hotspot editing and the PASSIGE™ platform extension). Two proprietary technology modules extend the platform: PASSIGE™ combines Prime Editing with integrase enzymes for gene-sized insertions, and Dual Flap (twin Prime Editors) enables deletions, large hotspot corrections, exon replacements, and sequence insertions without double-strand breaks.

The company is pre-revenue with no approved products; FY2025 net loss was approximately $201.1 million against a cash position of $191.4 million at year-end (and $149.2 million at end of Q1 2026), funded by a $315 million Series A-B round in 2021 (led by ARCH Venture Partners and GV), a $110 million upfront from the BMS ex vivo T-cell collaboration plus potential milestones exceeding $3.5 billion, approximately $39 million in cumulative Cystic Fibrosis Foundation grants, and a $144 million public offering in July 2025. Q1 2026 collaboration revenue was $4.6 million (up 55.3% year-over-year). The go-to-market is enterprise-pharma partnerships (BMS handles manufacturing and commercialization for ex vivo programs) and clinical trial execution for wholly-owned in vivo programs, with regulatory designations accumulated on PM359 including FDA RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease status. The company underwent a May 2025 strategic restructuring with a 25% workforce reduction, pivoting focus to liver diseases, cystic fibrosis, and partnered programs; clinical milestones include the first-in-human NEJM publication of Prime Editing data in December 2025 and New Zealand CTA clearance for PM577a in June 2026 marking the first in vivo Prime Editing clinical authorization.

Short descriptiontext

Prime Medicine is a clinical-stage biotechnology company developing Prime Editing-based gene therapies for rare genetic diseases across hematology, liver, and lung indications, operating through pharma partnerships and clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene editing therapies, prime editing platform, rare genetic diseases, cell therapy development, biotechnology research
Industry4 codes
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Gene Editing Biotechnology and Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Strategic Collaboration Revenue
TypeLicensing Royalties
Description

Prime Medicine receives upfront payments, research funding, and potential milestone payments from pharmaceutical partners. The Bristol Myers Squibb collaboration includes $110 million upfront and potential milestones exceeding $3.5 billion for ex vivo T-cell therapies.

investors.primemedicine.com
2Foundation Funding
TypeLicensing Royalties
Description

Non-dilutive funding from disease foundations supporting research programs. The Cystic Fibrosis Foundation provided up to $15 million initially and committed an additional $24 million for cystic fibrosis program development.

globenewswire.com
3Future Product Revenue
TypeOne Time License
Description

Pre-revenue company. Future revenue anticipated from commercialized gene editing therapies, though no products are currently approved. Q1 2026 revenue was $4.6 million (up 55.3%), likely from collaborations.

fool.com
4Equity Financing
TypeLicensing Royalties
Description

Raised $315 million through Series A and Series B funding rounds in 2021. Additional public equity offerings in 2025 raised approximately $144 million.

finsmes.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PASSIGE
Description

Prime Assisted Site Specific Integrase Gene Editing - a proprietary therapeutic approach combining Prime Editing with integrase enzymes to insert gene-sized sequences precisely in the genome.

primemedicine.com
Core offering1 text field

Prime Medicine develops investigational one-time curative gene editing therapies using its proprietary Prime Editing platform, which can search and replace disease-causing DNA sequences without double-strand breaks. The company is advancing clinical-stage programs for Chronic Granulomatous Disease (PM359), Wilson Disease (PM577), Alpha-1 Antitrypsin Deficiency (PM647), Cystic Fibrosis, and an ex vivo CAR-T cell therapy program partnered with Bristol Myers Squibb.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • PM359 achieved 66% DHR positivity by Day 30 in first patient (May 2025), exceeding the 20% threshold considered potentially curative. Second patient achieved 83% DHR neutrophils.
+3 more records
Product overview1 text field

Prime Medicine is a biotechnology company developing a diversified portfolio of investigational gene editing therapies organized around core areas: hematology/immunology/oncology, liver, and lung diseases. The company's core technology is the Prime Editing platform, a versatile gene editing approach that acts like a DNA word processor to search and replace genetic sequences. The portfolio includes clinical-stage programs: PM359 (ex vivo therapy for Chronic Granulomatous Disease), PM577 (in vivo liver therapy for Wilson Disease), PM647 (in vivo liver therapy for Alpha-1 Antitrypsin Deficiency), plus cystic fibrosis and CAR-T programs. Key technology modules include PASSIGE™ for gene-sized insertions and Dual Flap Prime Editing for broader genomic edits. Prime Editing can theoretically address about 90% of known disease-causing mutations across many organisms, organs and cell types, offering potentially curative one-time therapies.

Product and service5 records
1PM359
CategoryClinical Program - Ex Vivo Hematopoietic Therapy
Description

Investigational ex vivo autologous hematopoietic stem cell therapy using Prime Editing to treat p47phox-deficient Chronic Granulomatous Disease (CGD), delivered as an all-RNA Prime Editor via electroporation.

2PM577 (Wilson Disease Program)
CategoryClinical Program - In Vivo Liver Therapy
Description

Investigational in vivo liver-directed Prime Editing therapy targeting the ATP7B gene (H1069Q mutation) for Wilson Disease, delivered via lipid nanoparticle (LNP) technology.

3PM647 (Alpha-1 Antitrypsin Deficiency Program)
CategoryClinical Program - In Vivo Liver Therapy
Description

Investigational in vivo liver-directed Prime Editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), delivered via lipid nanoparticle (LNP) technology with preclinical data showing 95% protein restoration.

4Cystic Fibrosis Program
CategoryClinical Program - Lung Therapy
Description

Investigational lung-directed Prime Editing program for Cystic Fibrosis targeting CFTR mutations using hotspot editing and PASSIGE approaches, with initial focus on the G542X mutation.

5Ex Vivo CAR-T Cell Therapy Program
CategoryClinical Program - Cell Therapy
Description

Ex vivo T-cell therapy program using Prime Editing for CAR-T products, co-developed with Bristol Myers Squibb under a strategic collaboration where BMS handles development, manufacturing, and commercialization while Prime Medicine designs the gene editing reagents.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Bristol Myers Squibb
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-30
Description

Strategic collaboration and license agreement to develop and commercialize ex vivo T-cell therapies using Prime Editing technology. Prime Medicine designs gene editing reagents while Bristol Myers Squibb handles development, manufacturing, and commercialization. Prime receives $110 million upfront with potential milestones exceeding $3.5 billion. This is a major validation of Prime Editing technology for cell therapy applications.

investors.primemedicine.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Beam Therapeutics is a direct peer developing base editing, a closely related next-generation gene editing modality that also avoids double-strand DNA breaks. Both companies emerged from the David Liu / Broad Institute ecosystem and target similar monogenic and rare disease indications, including sickle cell disease and other hematologic conditions.

TypeDirect peer
Description

CRISPR Therapeutics is a direct peer and pioneer of CRISPR/Cas9-based gene editing therapies, with CASGEVY (exa-cel) becoming the first FDA-approved CRISPR therapy. Like Prime Medicine, it focuses on ex vivo and in vivo gene editing for rare genetic diseases and has established major pharma partnerships (Vertex).

TypeDirect peer
Description

Editas Medicine is a direct peer developing CRISPR/Cas9 and CRISPR/Cas12a gene editing therapies for serious diseases, including sickle cell disease and inherited retinal diseases. It competes with Prime Medicine for talent, partner attention, and clinical milestones in the gene editing field.

TypeDirect peer
Description

Intellia Therapeutics is a direct peer developing both ex vivo and in vivo CRISPR/Cas9 gene editing therapies, including programs for transthyretin amyloidosis and hereditary angioedema. Its in vivo LNP delivery approach for liver targets directly parallels Prime Medicine's liver-directed Prime Editing programs.

TypeDirect peer
Description

Verve Therapeutics is a direct peer developing in vivo base editing therapies for cardiovascular disease using LNP delivery. Like Prime Medicine's in vivo programs, it leverages lipid nanoparticle delivery to the liver and pursues one-time curative treatments, making its modality and delivery mechanism highly comparable.

TypeDirect peer
Description

Sangamo Therapeutics is a direct peer pioneering zinc finger nuclease (ZFN) gene editing and gene therapy for rare genetic diseases including hemophilia and lysosomal storage disorders. It is among the longest-operating clinical-stage genome editing companies, providing a comparable reference point for Prime Medicine's modality-focused pipeline.

7bluebird bio
TypeBroad incumbent
Description

bluebird bio is a broad incumbent in ex vivo gene therapy with approved products for beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy. Its ex vivo lentiviral gene therapy approach overlaps with Prime Medicine's ex vivo HSC program (PM359 for CGD), and Prime Medicine's CMO previously led clinical development at bluebird bio.

TypeOthers
Description

Moderna is an adjacent player whose LNP delivery platform technology overlaps with Prime Medicine's PM577 and PM647 in vivo liver-directed programs. While Moderna's primary focus is mRNA vaccines and therapeutics rather than gene editing, it represents a relevant reference for LNP manufacturing scale-up and a potential future partner or competitor for in vivo delivery.

TypeOthers
Description

Alnylam Pharmaceuticals is an adjacent peer in nucleic acid-based therapeutics, pioneering RNAi-based therapies for rare genetic diseases including hereditary ATTR amyloidosis and primary hyperoxaluria. It competes with Prime Medicine in liver-directed genetic disease treatment paradigms and LNP/GalNAc delivery approaches.

TypeOthers
Description

Vertex Pharmaceuticals is a strategic partner of Prime Medicine (BMS competing in CF space; also historically a partner for CASGEVY with CRISPR Therapeutics). Vertex's CF franchise (TRIKAFTA) represents both a near-term competitive threat and a potential commercialization partner for Prime Medicine's cystic fibrosis program.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prime Medicine

Gene Editing Biotechnology and Therapeuticsprimemedicine.com

Prime Medicine is a clinical-stage biotechnology company developing Prime Editing-based gene therapies for rare genetic diseases across hematology, liver, and lung indications, operating through pharma partnerships and clinical trials.

What Prime Medicine does

Prime Medicine, Inc. is a clinical-stage biotechnology company founded in 2019/2020 and headquartered at 21 Erie Street in Cambridge, Massachusetts, that develops Prime Editing-based gene editing therapies for rare genetic diseases. The company's core platform, Prime Editing, was developed in Dr. David R. Liu's lab at the Broad Institute of MIT and Harvard and published in Nature in December 2019; it acts as a "DNA word processor" to search and replace genetic sequences at their native genomic location without inducing double-strand DNA breaks, theoretically addressing approximately 90% of known disease-causing mutations. The product portfolio spans three therapeutic areas: hematology/immunology/oncology (PM359, an ex vivo autologous HSC therapy for p47phox Chronic Granulomatous Disease, and ex vivo CAR-T programs partnered with Bristol Myers Squibb), liver diseases (PM577a for H1069Q-mutated Wilson Disease via LNP delivery, and PM647 for Alpha-1 Antitrypsin Deficiency), and lung disease (a cystic fibrosis program supported by Cystic Fibrosis Foundation funding targeting hotspot editing and the PASSIGE™ platform extension). Two proprietary technology modules extend the platform: PASSIGE™ combines Prime Editing with integrase enzymes for gene-sized insertions, and Dual Flap (twin Prime Editors) enables deletions, large hotspot corrections, exon replacements, and sequence insertions without double-strand breaks.

The company is pre-revenue with no approved products; FY2025 net loss was approximately $201.1 million against a cash position of $191.4 million at year-end (and $149.2 million at end of Q1 2026), funded by a $315 million Series A-B round in 2021 (led by ARCH Venture Partners and GV), a $110 million upfront from the BMS ex vivo T-cell collaboration plus potential milestones exceeding $3.5 billion, approximately $39 million in cumulative Cystic Fibrosis Foundation grants, and a $144 million public offering in July 2025. Q1 2026 collaboration revenue was $4.6 million (up 55.3% year-over-year). The go-to-market is enterprise-pharma partnerships (BMS handles manufacturing and commercialization for ex vivo programs) and clinical trial execution for wholly-owned in vivo programs, with regulatory designations accumulated on PM359 including FDA RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease status. The company underwent a May 2025 strategic restructuring with a 25% workforce reduction, pivoting focus to liver diseases, cystic fibrosis, and partnered programs; clinical milestones include the first-in-human NEJM publication of Prime Editing data in December 2025 and New Zealand CTA clearance for PM577a in June 2026 marking the first in vivo Prime Editing clinical authorization.

Prime Medicine firmographics

Firmographics
Name
Prime Medicine
Legal name
Prime Medicine, Inc.
Website
https://primemedicine.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
Prime Medicine is a clinical-stage biotechnology company developing Prime Editing-based gene therapies for rare genetic diseases across hematology, liver, and lung indications, operating through pharma partnerships and clinical trials.
Ownership category
akta.pro rank

Prime Medicine industry classification

Industry
Product category
Gene Editing Biotechnology and Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene editing therapies
  • Prime editing platform
  • Rare genetic diseases
  • Cell therapy development
  • Biotechnology research

Where Prime Medicine is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Prime Medicine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Collaboration Revenue: Prime Medicine receives upfront payments, research funding, and potential milestone payments from pharmaceutical partners. The Bristol Myers Squibb collaboration includes $110 million upfront and potential milestones exceeding $3.5 billion for ex vivo T-cell therapies.
  2. Foundation Funding: Non-dilutive funding from disease foundations supporting research programs. The Cystic Fibrosis Foundation provided up to $15 million initially and committed an additional $24 million for cystic fibrosis program development.
  3. Future Product Revenue: Pre-revenue company. Future revenue anticipated from commercialized gene editing therapies, though no products are currently approved. Q1 2026 revenue was $4.6 million (up 55.3%), likely from collaborations.
  4. Equity Financing: Raised $315 million through Series A and Series B funding rounds in 2021. Additional public equity offerings in 2025 raised approximately $144 million.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Prime Medicine product offering

Product offering

Core offering

Prime Medicine develops investigational one-time curative gene editing therapies using its proprietary Prime Editing platform, which can search and replace disease-causing DNA sequences without double-strand breaks. The company is advancing clinical-stage programs for Chronic Granulomatous Disease (PM359), Wilson Disease (PM577), Alpha-1 Antitrypsin Deficiency (PM647), Cystic Fibrosis, and an ex vivo CAR-T cell therapy program partnered with Bristol Myers Squibb.

Product overview

Prime Medicine is a biotechnology company developing a diversified portfolio of investigational gene editing therapies organized around core areas: hematology/immunology/oncology, liver, and lung diseases. The company's core technology is the Prime Editing platform, a versatile gene editing approach that acts like a DNA word processor to search and replace genetic sequences. The portfolio includes clinical-stage programs: PM359 (ex vivo therapy for Chronic Granulomatous Disease), PM577 (in vivo liver therapy for Wilson Disease), PM647 (in vivo liver therapy for Alpha-1 Antitrypsin Deficiency), plus cystic fibrosis and CAR-T programs. Key technology modules include PASSIGE™ for gene-sized insertions and Dual Flap Prime Editing for broader genomic edits. Prime Editing can theoretically address about 90% of known disease-causing mutations across many organisms, organs and cell types, offering potentially curative one-time therapies.

Differentiator

Problem solved

Functional benefit

Brands

  • PASSIGE: Prime Assisted Site Specific Integrase Gene Editing - a proprietary therapeutic approach combining Prime Editing with integrase enzymes to insert gene-sized sequences precisely in the genome.

Products and services

  • PM359 Investigational ex vivo autologous hematopoietic stem cell therapy using Prime Editing to treat p47phox-deficient Chronic Granulomatous Disease (CGD), delivered as an all-RNA Prime Editor via electroporation.
  • PM577 (Wilson Disease Program) Investigational in vivo liver-directed Prime Editing therapy targeting the ATP7B gene (H1069Q mutation) for Wilson Disease, delivered via lipid nanoparticle (LNP) technology.
  • PM647 (Alpha-1 Antitrypsin Deficiency Program) Investigational in vivo liver-directed Prime Editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), delivered via lipid nanoparticle (LNP) technology with preclinical data showing 95% protein restoration.
  • Cystic Fibrosis Program Investigational lung-directed Prime Editing program for Cystic Fibrosis targeting CFTR mutations using hotspot editing and PASSIGE approaches, with initial focus on the G542X mutation.
  • Ex Vivo CAR-T Cell Therapy Program Ex vivo T-cell therapy program using Prime Editing for CAR-T products, co-developed with Bristol Myers Squibb under a strategic collaboration where BMS handles development, manufacturing, and commercialization while Prime Medicine designs the gene editing reagents.

Quantifiable outcome

  • PM359 achieved 66% DHR positivity by Day 30 in first patient (May 2025), exceeding the 20% threshold considered potentially curative. Second patient achieved 83% DHR neutrophils.
  • +3 more outcomes

Companies that use Prime Medicine

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Prime Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Prime Medicine partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Bristol Myers SquibbflagshipStrategic or Co-development Partner · 30 September 2024Strategic collaboration and license agreement to develop and commercialize ex vivo T-cell therapies using Prime Editing technology. Prime Medicine designs gene editing reagents while Bristol Myers Squibb handles development, manufacturing, and commercialization. Prime receives $110 million upfront with potential milestones exceeding $3.5 billion. This is a major validation of Prime Editing technology for cell therapy applications.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Prime Medicine competitors and assessment

Company assessment

Direct peers

  • Beam Therapeutics: Beam Therapeutics is a direct peer developing base editing, a closely related next-generation gene editing modality that also avoids double-strand DNA breaks. Both companies emerged from the David Liu / Broad Institute ecosystem and target similar monogenic and rare disease indications, including sickle cell disease and other hematologic conditions.
  • CRISPR Therapeutics: CRISPR Therapeutics is a direct peer and pioneer of CRISPR/Cas9-based gene editing therapies, with CASGEVY (exa-cel) becoming the first FDA-approved CRISPR therapy. Like Prime Medicine, it focuses on ex vivo and in vivo gene editing for rare genetic diseases and has established major pharma partnerships (Vertex).
  • Editas Medicine: Editas Medicine is a direct peer developing CRISPR/Cas9 and CRISPR/Cas12a gene editing therapies for serious diseases, including sickle cell disease and inherited retinal diseases. It competes with Prime Medicine for talent, partner attention, and clinical milestones in the gene editing field.
  • Intellia Therapeutics: Intellia Therapeutics is a direct peer developing both ex vivo and in vivo CRISPR/Cas9 gene editing therapies, including programs for transthyretin amyloidosis and hereditary angioedema. Its in vivo LNP delivery approach for liver targets directly parallels Prime Medicine's liver-directed Prime Editing programs.
  • Verve Therapeutics: Verve Therapeutics is a direct peer developing in vivo base editing therapies for cardiovascular disease using LNP delivery. Like Prime Medicine's in vivo programs, it leverages lipid nanoparticle delivery to the liver and pursues one-time curative treatments, making its modality and delivery mechanism highly comparable.
  • Sangamo Therapeutics: Sangamo Therapeutics is a direct peer pioneering zinc finger nuclease (ZFN) gene editing and gene therapy for rare genetic diseases including hemophilia and lysosomal storage disorders. It is among the longest-operating clinical-stage genome editing companies, providing a comparable reference point for Prime Medicine's modality-focused pipeline.

Broad incumbents

  • bluebird bio: bluebird bio is a broad incumbent in ex vivo gene therapy with approved products for beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy. Its ex vivo lentiviral gene therapy approach overlaps with Prime Medicine's ex vivo HSC program (PM359 for CGD), and Prime Medicine's CMO previously led clinical development at bluebird bio.

Others

  • Moderna: Moderna is an adjacent player whose LNP delivery platform technology overlaps with Prime Medicine's PM577 and PM647 in vivo liver-directed programs. While Moderna's primary focus is mRNA vaccines and therapeutics rather than gene editing, it represents a relevant reference for LNP manufacturing scale-up and a potential future partner or competitor for in vivo delivery.
  • Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is an adjacent peer in nucleic acid-based therapeutics, pioneering RNAi-based therapies for rare genetic diseases including hereditary ATTR amyloidosis and primary hyperoxaluria. It competes with Prime Medicine in liver-directed genetic disease treatment paradigms and LNP/GalNAc delivery approaches.
  • Vertex Pharmaceuticals: Vertex Pharmaceuticals is a strategic partner of Prime Medicine (BMS competing in CF space; also historically a partner for CASGEVY with CRISPR Therapeutics). Vertex's CF franchise (TRIKAFTA) represents both a near-term competitive threat and a potential commercialization partner for Prime Medicine's cystic fibrosis program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Prime Medicine social profiles

Digital presence

Prime Medicine compliance and trust

Trust signal

Compliance4 records

Prime Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prime Medicine leadership team

Management profile

Number of profiles

Profiles16 records

Prime Medicine funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prime Medicine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prime Medicine

What does Prime Medicine do?

Prime Medicine develops investigational one-time curative gene editing therapies using its proprietary Prime Editing platform, which can search and replace disease-causing DNA sequences without double-strand breaks. The company is advancing clinical-stage programs for Chronic Granulomatous Disease (PM359), Wilson Disease (PM577), Alpha-1 Antitrypsin Deficiency (PM647), Cystic Fibrosis, and an ex vivo CAR-T cell therapy program partnered with Bristol Myers Squibb.

Is Prime Medicine a public or private company?

Prime Medicine is a public company. It is classified as public and is currently operating.

When was Prime Medicine founded?

Prime Medicine was founded in 2020. It employs 101 to 250 people.

Where is Prime Medicine based?

Prime Medicine is headquartered in Cambridge, United States, in the North America region.

How does Prime Medicine make money?

Four revenue lines are on record. Strategic Collaboration Revenue is the primary driver. The others are foundation Funding, future Product Revenue and equity Financing.

Who are Prime Medicine's main competitors?

Direct peers on record are Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Verve Therapeutics and Sangamo Therapeutics. bluebird bio is listed as a broad incumbent. Others are Moderna, Alnylam Pharmaceuticals and Vertex Pharmaceuticals.

Does Prime Medicine have an API?

No public API is recorded for Prime Medicine.

What industry is Prime Medicine in?

Prime Medicine's product category is Gene Editing Biotechnology and Therapeutics. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaPrime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 TranscriptPrime Medicine CEO Allan Reine described the company's next-generation gene editing technology and its clinical pipeline. The company announced its first patient dose in the Wilson program and an active alpha-1 IND, with a first approval expected next year for chronic granulomatous disease.Investing.comPrime Medicine at Jefferies: pushes gene-editing pipeline, funding optionsPrime Medicine outlined its prime editing platform and rare-disease pipeline at Jefferies, highlighting Wilson disease and alpha-1 antitrypsin deficiency programs. The company expects Wilson disease data in 2027 and is seeking less dilutive funding sources after a recent capital raise. It also evaluates liver and cystic fibrosis opportunities.TradingViewHC Wainwright & Co. maintains Prime Medicine at Buy, keeps price target at $8HC Wainwright & Co. maintained Prime Medicine at Buy and kept its price target at $8. The target implies an upside of 87.4% from the Nov 13 close of $4.27. The firm's rating and target are unchanged.TradingViewPrime Medicine Prices $125 Million Stock Offering at $3.50 Per SharePrime Medicine entered an underwriting agreement for a public offering of 35.7 million common shares at $3.50 per share, raising about $125 million. The company plans to use the proceeds primarily to advance its Wilson disease and alpha-1 antitrypsin deficiency programs and other research and development activities.Business & FinancialPrime Medicine Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional SharesPrime Medicine closed its public offering and fully exercised underwriters' option to purchase additional shares. Jefferies, TD Cowen, and Goldman Sachs acted as joint book-running managers, with Oppenheimer and LifeSci Capital as passive managers. The offering was made under a Form S-3 shelf registration statement filed with the SEC.Seeking AlphaPrime Medicine prices $125M public offering at $3.50 per share (PRME:NASDAQ)Prime Medicine priced an underwritten public offering of 35.7 million shares at $3.50 per share, expecting to raise about $125 million in gross proceeds. The company expects the offering to close on or about November 12, and the stock fell about 4% after market hours.TradingViewPrime Medicine prices $125M public offering at $3.50 per sharePrime Medicine priced a public offering of 35.7 million shares at $3.50 per share, expecting to raise about $125 million. The company expects the offering to close on or about November 12, and the stock fell about 4% after market hours.Investing.comPrime Medicine commences $125 million public stock offeringPrime Medicine Inc. commenced an underwritten public offering of $125 million in common stock, with a 30-day option to buy up to $18.75 million more. The offering is subject to market conditions, and final terms will be disclosed in a prospectus supplement.Business & FinancialPrime Medicine To Present At Jefferies Global Healthcare ConferencePrime Medicine will present at the Jefferies Global Healthcare Conference, with a live webcast available on its website. The company is developing gene editing therapies using its Prime Editing platform, targeting liver, lung, and immunology/oncology programs. It plans to expand beyond current indications over time.BioSpacePlug-and-play gene therapy: FDA executes on vision that’s been in the works for yearsThe FDA released draft guidance to streamline biologics license applications for personalized gene therapies, allowing a single application to cover multiple variants. The guidance targets companies like Beam Therapeutics and Prime Medicine, which have products in development. The agency aims to accelerate access as new mutations are discovered weekly.